Functional Implications and Clinical Potential of MicroRNAs in Irritable Bowel Syndrome: A Concise Review
Academic Article in Scopus
-
- Overview
-
- Identity
-
- Additional document info
-
- View All
-
Overview
abstract
-
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.MicroRNAs (miRNAs) are tiny (20¿24 nucleotides long), non-coding, highly conserved RNA molecules that play a crucial role within the post-transcriptional regulation of gene expression via sequence-specific mechanisms. Since the miRNA transcriptome is involved in multiple molecular processes needed for cellular homeostasis, its altered expression can trigger the development and progression of several human pathologies. In this context, over the last few years, several relevant studies have demonstrated that dysregulated miRNAs affect a wide range of molecular mechanisms associated with irritable bowel syndrome (IBS), a common gastrointestinal disorder. For instance, abnormal miRNA expression in IBS patients is related to the alteration of intestinal permeability, visceral hyperalgesia, inflammatory pathways, and pain sensitivity. Besides, specific miRNAs are differentially expressed in the different subtypes of IBS, and therefore, they might be used as biomarkers for precise diagnosis of these pathological conditions. Accordingly, miRNAs have noteworthy potential as theragnostic targets for IBS. Hence, in this current review, we present an overview of the recent discoveries regarding the clinical relevance of miRNAs in IBS, which might be useful in the future for the development of miRNA-based drugs against this disorder.
status
publication date
published in
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional document info
has global citation frequency
start page
end page
volume